Latest Innovation News

Antilles Gold initiates a $650,000 share placement to fund working capital and prepare for a major $29.5 million EPC contract with Xinhai Mining, advancing the Nueva Sabana copper-gold mine development in Cuba.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Electro Optic Systems (EOS) has landed a landmark €71.4 million contract from a European NATO member for its pioneering 100kW high-power laser counter-drone system, marking the first export of this class of directed energy weapon.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Credit Corp Group delivered a robust FY25 with a 16% increase in net profit after tax, driven by US debt buying and Australian/NZ lending growth. The company sets an ambitious FY26 outlook, underpinned by a record US investment pipeline and new product launches.

TPG Telecom has unveiled pro forma financials reflecting its recent fibre network sale to Vocus, alongside updated FY25 guidance projecting EBITDA between $1.6 billion and $1.65 billion. The company signals a strategic pivot with fresh investments in satellite technology and IT systems.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Reckon Limited delivered a robust half-year performance in HY25, driven by strong cloud revenue growth and a key acquisition that expanded its SME client base. The company also declared a fully franked dividend, underscoring confidence in its ongoing strategy.

Reckon Limited has reported a robust first half of 2025, marked by significant revenue and profit growth fueled by organic expansion and the acquisition of Cashflow Manager. The company’s cloud-based Reckon One product and US-focused Legal Group continue to drive momentum.